The Dermatology Clinical Trials Unit is nationally recognized for developing and participating in clinical therapeutic trials. Clinical trials allow our patients to be exposed to experimental therapeutics. The trials unit is experienced in all areas of dermatologic clinical research from pre-Phase I to Phase IV. We are currently participating in a broad range of clinical trials of novel therapeutics for inflammatory and neoplastic skin disorders. The trials unit draws on the Division of Dermatology’s vast clinical experience.

Dermatology Clinical Trials Unit

Stephanie Farris, Clinical Research Coordinator
Phone: 314-747-8694 Fax: 314-362-6080

Justin Stout, Clinical Research Coordinator
Phone: 314-273-3737 Fax: 314-362-6080

Mary Tabacchi, CRCC, Sr. Clinical Research Coordinator
Phone: 314-362-8171 Fax: 314-362-6080

Milan Anadkat, MD, Director, Clinical Trials Unit 

Currently Enrolling Trials

Dr. Milan Anadkat

Phase 1, Open-Label, Dose Escalation Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy Study of Topically Administered LUT014 (BRAF agonist) in Metastatic Colorectal Cancer Patients with EGFR Inhibitor Induced Acneiform Lesions

A Phase II, Randomized, Placebo-controlled, Double-blind, Multiple Dose Study to Evaluate the Efficacy and Safety of ANB019 (IL-36R antagonist) in Subjects with Palmoplantar Pustulosis

Dr. Heather Jones

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate Efficacy and Safety of Lenabasum (Cannabanoid) in Dermatomyositis

Dr. Elizabeth Nieman

*Evaluation of the Pharmacokinetics and Safety of Upadacitinib (JAK-inhibitor) in Pediatric Subjects (ages 2-11) with Severe Atopic Dermatitis

Dr. Ann Martin

*A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream (JAK-inhibitor) Followed by an Extension Period in Participants with Vitiligo

Dr. Amy Musiek

Randomized, Double-Blind, Placebo-controlled study of Efficacy, Safety, and Tolerability of Serlopitant (neurokinin inhibitor) for the treatment of Chronic Pruritus of Unknown Origin

SOLAR: A Phase 2, Randomized, Open-label, Parallel-group, Active Comparator, Multi-center Study to Investigate the Efficacy and Safety of Cobomarsen (MRG-106) in Subjects with Cutaneous T-Cell Lymphoma (CTCL), Mycosis Fungoides (MF) Subtype

Phase 2A, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of PF-06823859 (IFN antagonist) in Adult Subjects with Dermatomyositis

A Double Blind, Randomized, Vehicle Controlled, Crossover Study to Evaluate the Safety and Efficacy of Topical Naloxone Hydrochloride Lotion 0.5% for the Relief of Pruritus in Patients with the Mycosis Fungoides (MF) or Sézary Syndrome (SS) Forms Form of Cutaneous T-Cell Lymphoma (CTCL)